Maya K. Leabman

IGM Biosciences, Inc.

Poster(s):

• Th110 - Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
  Thursday, June 20, 2024

  7:30 AM – 7:45 PM PT